Averna Therapeutics
Boston
About Averna Therapeutics
Exsilio's method is based on naturally occurring genetic elements that can accurately insert new genes into cells via RNA intermediate templates. Exsilio employs predictive in-silico modeling and wet lab-based experiments to create such elements for accurate insertion of therapeutic genes into safe harbor regions of disease-relevant cells.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $85.0M
- Funding stage: Early Stage Venture
- Last round: Series A (Jun 2024)
- Website: exsiliotx.com
- Phone: [email protected].
Industries & Categories
Biotechnology, Information Technology, Technical Support
Social Profiles
Canonical: https://fsome.com/organization/averna-therapeutics-59267 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.